ALK and non-small cell lung carcinoma: Thanks to the advancement in molecular biology and biotechnology, advanced driver-gene-positive NSCLC patients [such as epidermal growth factor receptor (EGFR), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), and anaplastic lymphoma kinase (ALK), etc.] could benefit from corresponding targeted therapy and their survival has been improved to some extent (5–7).